CASI Pharmeceuticals

Analyst Coverage

CASI Pharmaceuticals, Inc. is followed by the analyst(s) listed below. This list is provided for information purposes only. Please note that any opinions, estimates or forecasts regarding CASI Pharmaceutical’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CASI Pharmaceuticals or its management. Analysts may be contacted directly for copies of their reports.

HC Wainwright & Co. Swayampakula Ramakanth (RK), Ph.D. sramakanth@hcwco.com
Zacks Small Cap Research Grant Zeng, CFA gzeng@zacks.com

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →